Prof. Dr. Stefan Krause


Medizinische Klinik 5 - Hämatologie und Internistische Onkologie
Medizinische Fakultät

Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 5 Go to next page Go to last page

Braciak, T., Fenn, N., Wildenhain, S., Schiller, C., Roskopf, C., Schubert, I.,... Oduncu, F.S. (2019). Efficient Elimination of Cells from Patients with Different AML Subtypes by Dual-Targeting Triplebody 33-16-123. In ANNALS OF HEMATOLOGY (pp. S58-S58). NEW YORK: SPRINGER.
Ostgathe, C., Wendt, K.N., Heckel, M., Kurkowski, S., Klein, C., Krause, S.,... Stiel, S. (2019). Identifying the need for specialized palliative care in adult cancer patients - Development and validation of a screening procedure based on proxy assessment by physicians and filter questions. BMC Cancer, 19(1).
Middeke, J.M., Rollig, C., Kramer, M., Kramer, A., Bochtler, T., Scholl, S.,... Stoelzel, F. (2018). Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.
Saussele, S., Hehlmann, R., Fabarius, A., Jeromin, S., Proetel, U., Rinaldetti, S.,... Lauseker, M. (2018). Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 32(5), 1222-1228.
Braciak, T.A., Roskopf, C.C., Wildenhain, S., Fenn, N.C., Schiller, C.B., Schubert, I.A.,... Oduncu, F.S. (2018). Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. OncoImmunology, 7(9).
Stasik, S., Middeke, J.M., Kraemer, M., Rollig, C., Kramer, A., Scholl, S.,... Thiede, C. (2018). EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.
Schröder, S., Krause, S., & Erfurt-Berge, C. (2018). Genital ulcers as diagnostic clue for acute myeloid leukaemia. International Wound Journal.
Zierk, J., Arzideh, F., Haeckel, R., Rauh, M., Metzler, M., Ganslandt, T., & Krause, S. (2018). Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices. Clinical Chemistry and Laboratory Medicine.
Ugele, M., Weniger, M., Stanzel, M., Bassler, M., Krause, S., Friedrich, O.,... Richter, L. (2018). Label-Free High-Throughput Leukemia Detection by Holographic Microscopy. Advanced Science, 5(12).
Hochhaus, A., Saussele, S., Baerlocher, G.M., Bruemmendorf, T.H., Burchert, A., La Rosee, P.,... Pfirrmann, M. (2018). Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.

Zuletzt aktualisiert 2016-14-05 um 05:13